Category Archives: NMPA

CDE Seeks Input on Multivalent Vaccine Clinical Trial Q&A Guidelines

Beijing, Sept 4, 2026 — China’s Center for Drug Evaluation (CDE) has released for public comment a draft Q&A document accompanying its Technical Guidelines for Clinical Trials of Multivalent Vaccines, aiming to refine regulatory standards for combination vaccine development by addressing common questions encountered in clinical research, with a comment window of one month from publication.

Consultation Snapshot

Attribute	Detail
Document	Q&A Document of the Technical Guidelines for Clinical Trials of Multivalent Vaccines (Draft for Comments)
Issuing body	Center for Drug Evaluation (CDE), NMPA
Basis	Published Technical Guidelines for Clinical Trials of Multivalent Vaccines
Purpose	Address common issues and further refine regulatory standards for combination vaccine clinical R&D
Comment period	One month from publication (Sept 4, 2026)
Contacts	liuyalin@cde.org.cn; pany@cde.org.cn; suy@cde.org.cn

Regulatory Context

Multivalent vaccines—known in Chinese regulatory parlance as “多联疫苗,” or combination vaccines—deliver antigens against multiple pathogens in a single formulation, exemplified by products such as the pentavalent DTP-IPV-Hib vaccine. Combination vaccines raise distinctive clinical trial questions that single-antigen products do not: immune interference between components, comparability with co-administered or predecessor vaccines, choice of immunobridging strategies, and consistency of batch-to-batch immunogenicity across multiple antigens. The CDE’s underlying guideline established the framework for such trials; the new Q&A document drills into recurring issues sponsors face when designing programs, offering granular interpretation that converts principle-level text into actionable standards for trial design, endpoint selection and submission packages.

Market Impact Analysis

For China’s fast-growing vaccine sector, the Q&A document lowers a key source of development uncertainty. Domestic manufacturers—several of which are pursuing combination vaccines to upgrade beyond single-antigen pediatric products—have faced ambiguity on how much comparability data regulators expect against licensed combination or component vaccines, and on acceptable immunobridging pathways. Clarified answers should compress pre-submission negotiation cycles, reduce the risk of costly trial redesigns, and give sponsors firmer ground for portfolio planning in pediatric and adult combination products.

The timing is notable: China’s vaccine market is undergoing consolidation and technological upgrading following the rollout of the Vaccine Administration Law, and combination vaccines represent one of the clearest premium segments where domestic players still trail imported pentavalent and hexavalent products. By refining guidance now, the CDE is supporting the domestic pipeline’s ability to compete in high-value multivalent formulations—an area with strong public health rationale, since combination vaccines improve immunization coverage and reduce injection burden for infants.

The one-month comment window, standard for CDE guideline consultations, suggests a near-term finalization timeline, with the final Q&A potentially in force before mid-2027.

Forward-Looking Statement

Industry participants are expected to submit feedback to the CDE’s designated contacts before the deadline in early October 2026, with the final Q&A document likely issued after the agency reviews and incorporates comments. Once adopted, the clarified standards should accelerate clinical trial initiation and review for combination vaccine candidates, and market watchers will look for specificity on immune-interference evaluation, comparability requirements against licensed products, and immunobridging acceptance criteria—the provisions most likely to shape development costs and timelines. The document also signals continued build-out of China’s vaccine regulatory toolkit, with future refinements anticipated as domestic multivalent candidates advance into late-stage trials and registration.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/bb2cfb685e7dde58e2dbc39b09f1dd3d

CDE Opens Comment Period on TCM Specification Change Guidelines

Leave a reply

Beijing, Sept 4, 2026 — China’s Center for Drug Evaluation (CDE) has released for public comment a draft technical guideline governing specification changes to already-marketed traditional Chinese medicine (TCM) products, refining requirements set out in the agency’s existing trial guideline on pharmaceutical changes for marketed TCM drugs, with a comment window of one month from publication.

Consultation Snapshot

Attribute	Detail
Document	Technical Guidelines for Research on Changes in Specifications of Listed TCM (Draft for Comments)
Issuing body	Center for Drug Evaluation (CDE), NMPA
Purpose	Detail specification-change requirements under the trial guideline on pharmaceutical changes for marketed TCM
Comment period	One month from publication (Sept 4, 2026)
Contact	Department of TCM and Ethnic Drug Pharmacy Affairs
Email	zyyxzdyz@cde.org.cn (subject line must read “Specification Change”)

Regulatory Context

In China’s post-approval change framework, “specifications” (规格) define a marketed drug’s dosage strength, unit-dose content or package configuration. For traditional Chinese medicines—spanning tablets, capsules, granules and oral liquids—specification changes are frequently needed to match clinical dosing practice, improve pediatric or geriatric usability, or align products with updated manufacturing scales. The draft guideline builds on the Technical Guidelines for Pharmaceutical Change Research of Listed TCM (Trial), which established a risk-based classification for post-approval changes to marketed Chinese patent medicines. The new document isolates specification changes for dedicated treatment, giving manufacturers a clearer evidentiary roadmap—covering pharmaceutical equivalence, quality consistency and, where warranted, clinical bridging studies—for filing such changes with provincial or national regulators.

Market Impact Analysis

The consultation addresses a long-standing friction point for China’s TCM sector: many marketed Chinese patent medicines carry legacy specifications that no longer fit modern clinical demand, yet holders have lacked granular guidance on the research package needed to change them. By detailing the requirements, CDE is effectively lowering the regulatory uncertainty around specification amendments—reducing the risk that holders over-invest in unnecessary bridging studies or under-invest and face rejection.

For TCM manufacturers, the guideline creates a practical pathway to refresh aging product portfolios: adjusting strengths to match evidence-based dosing, consolidating multiple specifications for supply-chain efficiency, or improving patient adherence through better-suited dosage configurations. The CDE frames the initiative explicitly as serving clinical medication needs and supporting the development of the TCM industry, consistent with Beijing’s broader policy push to modernize traditional Chinese medicine under dedicated state support measures.

The one-month comment window—standard for CDE technical guideline consultations—signals an intent to finalize the guideline on a near-term timeline, suggesting specification-change filings under the new framework could begin well before mid-2027.

Forward-Looking Statement

Industry participants are expected to submit feedback to the CDE’s TCM and Ethnic Drug Pharmacy department before the deadline in early October 2026, with the final guideline likely issued after the agency reviews and incorporates comments. Once adopted, the guideline should produce a measurable uptick in specification-change applications for marketed TCM products as holders align legacy specifications with current clinical practice. Market watchers will look for clarity in the final text on risk classification thresholds, the conditions triggering clinical bridging requirements, and consistency-evaluation standards—provisions that will determine how readily smaller TCM manufacturers can utilize the pathway. The draft also points toward continued refinement of China’s post-approval change system for traditional medicines, potentially extending to other change categories in future guideline iterations.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/c5da4ee5650bdab08619259372885f93

China Includes SZJ0107 Tablets in ALS… correction: Rare Disease Care Plan Extension Pilot

Leave a reply

Beijing, Sept 4, 2026 — China’s Center for Drug Evaluation (CDE) has included SZJ0107 tablets, developed by Anhui Sanzhijian Pharmaceutical Technology Co., Ltd., in the “Care Plan Extension” pilot project for encouraging innovative drug R&D for rare diseases, targeting spinocerebellar ataxia (SCA), the agency announced in a formal inclusion notice dated Sept 4, 2026.

Program Snapshot

Attribute	Detail
Program	Care Plan Extension (Rare Disease Innovative Drug R&D Incentive Pilot)
Product	SZJ0107 Tablets
Applicant	Anhui Sanzhijian Pharmaceutical Technology Co., Ltd.
Indication	Spinocerebellar ataxia (SCA)
Notice type	Formal pilot inclusion (not a public consultation)
Issuing body	Center for Drug Evaluation (CDE), NMPA
Date	Sept 4, 2026

Clinical Context

Spinocerebellar ataxia refers to a group of hereditary neurodegenerative disorders characterized by progressive degeneration of the cerebellum and its connections, leading to worsening coordination of gait, speech and limb movements. More than 40 genetic subtypes have been identified, with SCA3 (Machado-Joseph disease) the most prevalent form in China. No disease-modifying therapy is currently approved for SCA—treatment remains supportive—and the condition is listed in China’s official rare disease catalog, with estimated prevalence of roughly 3 to 6 per 100,000. The absence of any approved therapy and the progressive, disabling nature of the disease place SCA among the highest-unmet-need areas in neurology.

Market Impact Analysis

Unlike proposal-stage listings that open a public comment window, this notice confirms SZJ0107’s formal inclusion in the Care Plan Extension pilot—meaning the asset immediately qualifies for the program’s incentive package, which typically encompasses enhanced regulatory communication, rolling data submissions and potential priority pathways for rare disease candidates.

For Anhui Sanzhijian, a regional pharmaceutical technology company, the designation elevates a niche neurology asset into China’s premier rare disease fast-track framework, improving both development economics and partnering visibility. SCA represents a strategically underserved space: global developers have historically deprioritized it due to small patient populations and genetically heterogeneous trial designs, yet recent advances in genetic and targeted therapeutic approaches are reviving interest worldwide. By channeling a domestic SCA candidate into the pilot, CDE is signaling intent to build indigenous capability in rare neurodegenerative diseases rather than rely on imported therapies.

The inclusion also adds momentum to the Care Plan Extension cohort itself, demonstrating that the program is actively admitting CNS and neurodegenerative indications beyond its initial focus areas, which could encourage additional submissions from small and mid-cap Chinese biotechs pursuing orphan neurology assets.

Forward-Looking Statement

Industry observers expect SZJ0107 to advance clinical development under the pilot’s enhanced regulatory support, with the formal inclusion potentially compressing trial-to-review timelines if the program generates positive efficacy and safety data in SCA populations. Progress toward registration would mark a potential first-in-class outcome for spinocerebellar ataxia in China, establishing proof-of-concept for the Care Plan Extension in hereditary ataxias and opening pathways for related neurodegenerative rare disease candidates. The inclusion further reinforces China’s strategic push to localize rare disease drug innovation and expand treatment options for patients currently limited to supportive care. Further details on SZJ0107’s development stage and trial plans are expected to emerge from the applicant as the program advances.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/074dea77e97b316fc1c783cc0091937b